KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.

Matthias Karst, Winfried Meissner, Sabine Sator, Jens Keßler, Volker Schoder, Winfried Häuser

Nat Med 31(12) 4189-4196

PMID41023483
PMCIDPMC12705446
DOI10.1038/s41591-025-03977-0
发表日期2025-09-30
入排依据:未发现恶性肿瘤人群证据。
已检查 4 张 PubMed Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:AI 判定为 flow diagram;Fig. 3:森林图/亚组分析图;Extended Data Fig. 1:AI 判定为 other。
摘要

摘要

Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04940741 .

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1. CONSORT chart of the trial. The efficacy, safety and tolerability analyses included all randomized participants who received at least one dose of the study medication during the respective study phase.
非 KM Figure
Fig. 2Fig. 2. Trial design. a , The trial design of phase A. b , The trial design of phases B–D. WO, washout.
非 KM Figure
Fig. 3Fig. 3. Effect of VER-01 on NRS pain and NPSI scores as compared with Placebo. a , Mean NRS pain intensity in phases A and B, as measured on an 11-point NRS for each study week of the placebo-controlled study phase A (VER-01, n = 390; placebo, n = 425) and the open-label phase B (VER-01, n = 524). b , Mean NPSI total scores for the subgroup of participants with a neuropathic pain component during phase A (VER-01, n = 88; placebo, n = 91). c , Change in mean NRS pain intensity after randomized withdrawal in phase D (VER-01, n = 51; placebo, n = 63). All bars display the range from mean ± s.e. of the mean. BL, baseline; W, week; Titr., titration.
非 KM Figure
Extended Data Fig. 1Extended Data Fig. 1. Weekly mean of daily dose of VER-01 and placebo in phase A and VER-01 in phase B. Bars display the range from mean ± standard error of the mean. Titr., titration.
非 KM Figure